Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
OPERATING ACTIVITIES    
Net income $ 7,404 $ 4,591
Adjustments to reconcile net income to net cash provided by operating activities:    
Provision for doubtful accounts 569 102
Depreciation 9,001 9,236
Loss on disposal of and reserve adjustments for medical equipment 854 337
Gain on sale of medical equipment (323) (2,282)
Amortization of intangible assets 549 709
Amortization of deferred debt issuance costs 63 61
Stock-based compensation 3,719 3,091
Deferred income taxes 2,429 2,530
Changes in assets - (increase)/decrease:    
Accounts receivable (8,159) (2,167)
Inventories 720 941
Other current assets 260 (762)
Other assets 555 1,028
Changes in liabilities - (decrease)/increase:    
Accounts payable and other liabilities 450 (133)
NET CASH PROVIDED BY OPERATING ACTIVITIES 18,091 17,282
INVESTING ACTIVITIES    
Acquisition of business 0 (1,412)
Purchase of medical equipment (8,712) (5,341)
Purchase of property and equipment (321) (427)
Proceeds from sale of medical equipment, property and equipment 1,280 2,582
NET CASH USED IN INVESTING ACTIVITIES (7,753) (4,598)
FINANCING ACTIVITIES    
Principal payments on long-term debt (16,742) (44,265)
Cash proceeds from long-term debt 16,742 41,502
Debt issuance costs 0 (230)
Common stock repurchased as part of share repurchase program (4,963) (8,563)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (799) (1,036)
Cash proceeds from exercise of options and ESPP 1,346 336
NET CASH USED IN FINANCING ACTIVITIES (4,416) (12,256)
Net change in cash and cash equivalents 5,922 428
Cash and cash equivalents, beginning of period 3,186 527
Cash and cash equivalents, end of period $ 9,108 $ 955